Consultations in Molecular Diagnostics

Detection of an Apparent Homozygous 3120G>A Cystic Fibrosis Mutation on a Routine Carrier Screen

Denise LaMarche Heaney,* Patrick Flume,[†]
Lauren Hamilton,[‡] Elaine Lyon,[§] and
Daynna J Wolff*

From the Departments of Pathology and Laboratory Medicine*
and Medicine,[†] Medical University of South Carolina, Charleston,
South Carolina; Charleston OB/GYN,[‡] Charleston, South
Carolina; and ARUP Laboratories and Department of Pathology,[§]
University of Utah, Salt Lake City, Utah

A 28-year-old Caucasian female with no personal or family history of cystic fibrosis (CF) presented for preconception counseling and screening. Cystic fibrosis transmembrane conductance regulator (CFTR) mutation analysis using the Inno-LiPa CFTR assay revealed lack of hybridization for both the wild-type and mutant oligonucleotides for 3120+1G>A. This region was sequenced, and an apparent homozygous 3120G>A mutation was detected. Additional testing revealed an abnormal sweat chloride (77 mmol/L). Review of systems was essentially unremarkable with an absence of sinus symptoms, occasional nonproductive cough, and no features of malabsorption. Physical examination, chest X-ray, and pulmonary function tests were within normal limits. Only two other patients (siblings) with homozygous 3120G>A mutations have been reported (<http://www.genet.sickkids.on.ca/cftr/>). Both siblings had pancreatic insufficiency, mild pulmonary symptoms, and abnormal sweat chloride levels. Our findings suggest that a homozygous mutation of a G>A conversion at 3120 is associated with abnormal CFTR function and either a mild form of CF or no overt symptoms of disease, emphasizing the difficulties in assigning genotype/phenotype correlation. (J Mol Diagn 2006, 8:137-140; DOI: 10.2353/jmoldx.2006.050065)

Cystic fibrosis (CF) is one of the most common autosomal recessive genetic disorders among the Caucasian population with a carrier rate of 1 in 29 and a disease frequency of 1 in 3300.¹⁻³ CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene located on chromosome 7q, resulting in a

chloride ion channel defect.⁴⁻⁷ This defect affects mucus-producing organs including the lungs, pancreas, sweat glands, and reproductive organs.

In 1997, the National Institutes of Health recommended that the United States begin implementing preconception or prenatal carrier screening for CF. Following that recommendation, the American College of Medical Genetics and the American College of Obstetrics and Gynecology published guidelines for carrier CF screening including testing a core panel of the 25 most common mutations among the Caucasian population^{2,8,9} that has been recently changed to 23 mutations.¹⁰ The guidelines recommended that CF mutation screening should be offered to individuals with a family history of CF, reproductive partners of individuals with CF, couples planning a pregnancy or seeking prenatal care when one or both partners are Caucasian or Ashkenazi Jewish, and individuals from other ethnic groups who chose to be screened. The goal of screening for CF gene mutation carriers was to provide appropriate genetic counseling for family planning.

An issue with population screening is the identification of two apparent disease-causing mutations in individuals without a diagnosis of CF. A recent study of 335,204 patients screened for carrier status revealed four individuals with two CF mutations who had not been previously diagnosed with CF.¹¹ This study underscored the lack of definitive genotype/phenotype correlations and discussed the counseling dilemmas associated with such findings. We report a patient who was referred for carrier screening and was found to have two rare mutations but exhibited no overt clinical features of CF.

Patient History

A 28-year-old Caucasian female presented to her gynecologist for preconception counseling. Although there was no family history of CF, the patient chose to have mutation screening. She had a history of bronchitis and

Accepted for publication September 14, 2005.

Address reprint requests to Denise LaMarche Heaney, Department of Pathology and Laboratory Medicine, 165 Ashley Ave., Suite 309, Charleston, SC 29425. E-mail: lamarche@musc.edu.

Figure 1. The Inno-LiPa CFTR33 assay results. An example of the assay's strips is shown on the **right**. The patient's results (**left**) show the absence of both the wild-type and mutant bands (**arrows**) for 3120+1 G>A.

chronic cough, which was attributed to smoking, but was an otherwise healthy young adult.

Molecular Studies

Inno-LiPa CFTR33 Assay

The Inno-LiPa CFTR33 Assay (Innogenetics NV, Brussels, Belgium) was used to screen for CF mutations. In brief, the peripheral blood DNA sample underwent multiplex amplification of the *CFTR* gene using biotinylated primers. Following amplification, the double-stranded DNA was chemically denatured and hybridized to oligonucleotide probes for the wild-type and mutant CF sequences bound to nitrocellulose strips. After hybridization, streptavidin labeled with alkaline phosphatase was applied and bound to biotinylated amplicon-probe hybrids. Incubation with a substrate (chromogen) solution resulted in formation of a purple precipitate. The reaction was stopped by washing, and the reactivity pattern of the probes was analyzed.

Upon analysis of the patient's results, absence of both the wild-type and mutant bands for the 3120+1G>A CF mutation was noted (Figure 1). The result was confirmed by performing a second Inno-LiPa test on the patient's original sample.

Sequencing the Region of Interest

To determine the cause of the unusual result from the CFTR33 mutation assay, sequencing of the region (exon 16) was performed. PCR products were generated using primers that flank exon 16 (including the exonic/intronic boundaries) of the *CFTR* gene. Products were sequenced bi-directionally using BigDye Terminator sequencing chemistry version 1.0 (Applied Biosystems, Foster City, CA). Unincorporated dye-labeled dideoxynucleotides were removed using Sephadex G50 fine (Sigma, St. Louis, MO). Sequencing reactions were electrophoresed using standard sequencing protocols on an AB 3100 capillary genetic analyzer. Sequences were aligned to the *CFTR* reference sequence. The sequence analysis revealed an apparent homozygous G to A mutation at position 3120 (Figure 2), explaining the Inno-LiPa results. The 3120 mutation apparently interfered with the binding of the PCR product to the wild-type and mutant 3120+1G>A targets on the Inno-LiPa strips (Figure 1).

Patient Clinical Follow-Up

Following the results of our molecular studies, the patient was referred to a pulmonologist. On examination, her height was 5 feet, 4 inches, and her weight was 111 lbs.

Figure 2. Patient's DNA sequence analysis of the region of interest (exon 16). The electropherogram shows the patient's results (top-forward sequence; bottom-reverse sequence) and indicates a base change of a G (highlighted box) to an A at the 3120 position.

Chest X-ray and pulmonary function tests were normal. She exhibited no sinus symptoms and no clinical features of malabsorption. She was noted to have an elevated sweat chloride (77 mmol/L) and a history of an occasional nonproductive cough. She declined additional diagnostic evaluation to assess pancreatic function and the presence of bronchiectasis. Attempts to obtain additional information and parental samples for carrier screening studies and/or uniparental disomy studies were declined. Parental consanguinity was denied.

Discussion

The presentation and course of CF is highly variable. Although most cases of CF are diagnosed before the age of 1, some cases do not come to medical attention until adolescence or adulthood.⁹ The presentation of CF cases can vary from severe pulmonary and/or gastrointestinal symptoms to mild disease⁹ or, as in this case, no overt symptoms of disease. The currently accepted criteria for the diagnosis of CF include evidence of a CFTR abnormality plus one of the following: one or more characteristic phenotypic features, a history of CF in a sibling, or a positive screening test.^{12,13} Our patient's assessment met the criterion based on her abnormal sweat chloride and having two CF mutations. However, if she had not presented for carrier screening, she would not have obtained a diagnosis.

3120G>A is considered a rare CF mutation, having only been reported in three other patients, including two siblings who were homozygous for 3120G>A mutation with pancreatic insufficiency, mild pulmonary symptoms,

and abnormal sweat chlorides (>80 mmol/L) and one patient with a severe phenotype carrying the delF508 mutation on the other allele (Cystic Fibrosis Mutation Database, <http://www.genet.sickkids.on.ca/cftr/>; Hospital for Sick Children, Toronto, Canada). Given the rarity of the 3120G>A mutation, it is unlikely that both of this patient's parents would be carriers. There are at least two possible mechanisms that could explain the results. One possible mechanism for the apparent homozygosity for this rare *CFTR* mutation is uniparental disomy for chromosome 7 (UPD7). Several cases of UPD7 and homozygosity of a *CFTR* mutation have been reported.^{14–16} In addition to having the classical symptoms associated with CF, patients with UPD7 also displayed growth retardation and short stature (~80% of the cases). Our patient was reported by the referring physician to have a small body frame with a disproportionately large head. These observations along with the homozygous 3120G>A *CFTR* mutation suggest that she may in fact have UPD7.

A second possible mechanism is that our patient is hemizygous because of a large deletion of the *CFTR* gene on the other chromosome that spans the same region as the 3120G>A mutation. Even though few have been characterized, large germline deletions of the *CFTR* gene have been suggested to account for 1 to 30% of the disease alleles that have not yet been identified.¹⁷ Although this mechanism could explain our findings, it seems to be an even more likely explanation for the more severe phenotype observed in the two siblings previously reported. Their phenotypes could be due to the inheritance of a large deletion from one parent, along with inheritance of the 3120G>A mutation from the other parent.

The presence of a modifier affecting the 3120G>A *CFTR* mutation may also explain the different phenotypes seen in this patient and the other reported homozygotes. Similar to I148T influencing 3199del6 in *cis*^{18,19} or R117H being influenced by the 5T variant,²⁰ there could be an additional mutation on the same chromosome causing different phenotypes for those who have the same apparent genotype.

Technical anomalies leading to the incorrect interpretation of the patient's results cannot be excluded. Although it is feasible to have a separate mutation that interferes with the priming from one allele, this is unlikely because of agreement of the sequencing and Inno-LiPa results along with the fact that the two methods have different primer binding sites (C. Van Loon, Innogenetics NV; A. Alexander, Innogenetics Inc., personal communication).

This case demonstrates that counseling patients who meet laboratory criteria for a CF diagnosis but do not have clinical symptoms of CF is problematic. Given the large numbers of individuals who are undergoing screening for *CFTR* mutations because of the recommendations made by the American College of Medical Genetics and the American College of Obstetrics and Gynecology, it is likely that other such individuals will be ascertained. The rare mutations detected in these nonsymptomatic patients may not represent independent disease-causing

mutations, and care is advised in offering phenotypic predictions.

Acknowledgments

We thank Dr. Denise Quigley for critical reading of this manuscript.

References

1. American College of Obstetrics and Gynecology and American College of Medical Genetics: Preconception and Prenatal Carrier Screening for Cystic Fibrosis, Clinical and Laboratory Guidelines. Washington, DC, American College of Obstetrics and Gynecology, 2001
2. Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ: Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. *Genet Med* 2001, 3:149–154
3. Palomaki GE, Haddow JE, Bradley LA, FitzSimmons SC: Updated assessment of cystic fibrosis mutation frequencies in non-Hispanic Caucasians. *Genet Med* 2002, 4:90–94
4. Rommens JM, Iannuzzi MC, Kerem B-S, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N: Identification of the cystic fibrosis gene: chromosome walking and jumping. *Science* 1989, 245:1059–1065
5. Riordan JR, Rommens JM, Kerem B-S, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsky N, Chou JL: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science* 1989, 245:1066–1073
6. Kerem B-S, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC: Identification of the cystic fibrosis gene: genetic analysis. *Science* 1989, 245:1073–1080
7. Tsui LC: The cystic fibrosis transmembrane regulator gene. *Am J Respir Crit Care Med* 1995, 151:S47–S53
8. Genetic testing for cystic fibrosis. NIH Consensus Statement 1997, 15:1–37
9. National Institutes of Health Consensus Development Conference Statement. Genetic testing for cystic fibrosis. *Arch Intern Med* 1999, 159:1529–1539
10. Watson MS, Cutting GR, Desnick RJ, Driscoll DA, Klinger K, Mennuti M, Palomaki GE, Popovich BW, Pratt VM, Rohlf EM, Strom CM, Richards CS, Witt DR, Grody WW: Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. *Genet Med* 2004, 6:387–391
11. Strom CM, Crossley B, Redman JB, Buller A, Quan F, Peng M, McGinnis M, Sun W: Cystic fibrosis screening: lessons learned from the first 320,000 patients. *Genet Med* 2004, 6:136–140
12. Rosenstein BJ, Cutting GR: The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. *J Pediatr* 1998, 132:589–596
13. Lotem Y, Barak A, Mussaffi H, Shohat M, Wilschanski M, Sivan Y, Blau H: Reaching the diagnosis of cystic fibrosis: the limits of the spectrum. *Isr Med Assoc J* 2000, 2:94–98
14. Spence JE, Perciaccante RG, Greig GM, Willard HF, Ledbetter DH, Hejtmancik JF, Pollack MS, O'Brien WE, Beaudet AL: Uniparental disomy as a mechanism for human genetic disease. *Am J Hum Genet* 1988, 42:217–226
15. Voss R, Ben-Simon E, Avital A, Godfrey S, Zlotogora J, Dagan J, Tikochinski Y, Hillel J: Isodisomy of chromosome 7 in a patient with cystic fibrosis: could uniparental disomy be common in humans? *Am J Hum Genet* 1989, 45:373–380
16. Spotila LD, Sereda L, Prockop DJ: Partial isodisomy for maternal chromosome 7 and short stature in an individual with a mutation at the COL1A2 locus. *Am J Hum Genet* 1992, 51:1396–1405
17. Audrezet MP, Chen JM, Raguenes O, Chuzhanova N, Giteau K, Le Marechal C, Quere I, Cooper DN, Ferec C: Genomic rearrangements in the CFTR gene: extensive allelic heterogeneity and diverse mutational mechanisms. *Hum Mutat* 2004, 23:343–357
18. Strom CM, Huang D, Buller A, Redman J, Crossley B, Anderson B, Entwistle T, Sun W: Cystic fibrosis screening using the college panel: platform comparison and lessons learned from the first 20,000 samples. *Genet Med* 2002, 4:289–296
19. Rohlf EM, Zhou Z, Sugarman EA, Heim RA, Pace RG, Knowles MR, Silverman LM, Allitto BA: The I148T allele occurs on multiple haplotypes: a complex allele is associated with cystic fibrosis. *Genet Med* 2002, 4:319–323
20. Kieseewetter S, Macek M Jr, Davis C, Currstin SM, Chu CS, Graham C, Shrimpton AE, Cashman SM, Tsui LC, Mickle J: A mutation in CFTR produces different phenotypes depending on chromosomal background. *Nat Genet* 1993, 5:274–278